A Agilent Technologies Inc.

Agilent at ASMS 2024: Driving Scientific Breakthroughs with Unparalleled Mass Spec Solutions

, (NYSE: A) will showcase its latest mass spectrometry innovations at the , scheduled for June 2 - 6, 2024, in Anaheim, California. A global leader in analytical instruments, Agilent continues to drive performance and accessibility in mass spectrometry.

“Agilent will make a significant impact at this year’s ASMS Conference, unveiling cutting-edge mass spectrometry solutions that deliver intelligence-driven performance that is beyond all limits,” exclaimed Ken Suzuki, vice president and general manager of Agilent’s Mass Spectrometry Division. enhance performance, streamline workflows, and provide powerful data insights, opening doors to new research frontiers.”

Agilent’s breakthroughs in mass spectrometry include the , an ultrahigh-performance instrument designed for research and testing labs analyzing large sample batches. It achieves parts per quadrillion (ppq)-level detection limits for challenging analytes in diverse sample matrices, such as omics, food, and environmental analysis.

In addition, Agilent’s is a next-generation, hybrid quadrupole time-of-flight mass spectrometer. It revolutionizes identification with rock-solid evidence, accurate mass measurements, and high-resolution data for targeted and untargeted analysis. Applications include food safety, metabolomics, and other discovery-based studies.

“Stay tuned for exciting announcements about additional GC/MS and LC/MS products and solutions launching at ASMS this year. These innovative offerings will provide next-level intelligence, unmatched sensitivity, and industry-leading robustness,” Suzuki added.

Agilent will hold several events at ASMS 2024, including two User Group Meetings (for LC/ Triple Quadrupole and Ion Mobility) on Sunday, June 2, from 9:30 a.m. to 4:30 p.m. at the Doubletree Hotel in Anaheim. Agilent will also host six breakfast sessions Monday, June 3, through Wednesday, June 5, from 7:00 to 8:00 a.m. at the Anaheim Convention Center (rooms 212 AB and 213 D) where key customers will present their research. Additional information on these and other events is available at .

ASMS attendees are invited to visit Agilent's Exhibition Booth #300 at the Anaheim Convention Center and the Agilent Hospitality Suite at the Anaheim Marriott, Marquis Ballroom South, from Monday, June 3 to Wednesday, June 6, from 8:00 to 10:30 p.m. Agilent is a corporate member of ASMS and multi-year co-sponsor of the annual event.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the . Follow Agilent on and .

EN
22/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch